home   |   contact us  

  Patient Home Page

  About the Registries

  Who Treats Stroke

  FAQs

  Participating Physicians

  Treatment Centers

  Links

  Articles / Trials
   

 
ARTICLES / TRIALS
 
References
 
  1. Kappelle LJ, Adams HP Jr, Heffner ML, Torner JC, Gomez F, Biller J. Prognosis of young adults with ischemic stroke. A long-term follow-up study assessing recurrent vascular events and functional outcome in the Iowa Registry of Stroke in Young Adults. Stroke 1994; 25: 1360-1365.
  2. Vogel J. Five-year follow-up of stroke patients over age 65. Rehabilitation 1994; 33: 155-157.
  3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM 1995; 333: 1581-1587.
  4. Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. JAMA 2000; 283: 2395-2403.
  5. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000; 31: 601-609.
  6. Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997;28 : 2338-2346.
  7. Horn J, de Haan RJ, Vermeulen M, et al. Very Early Nimodipine Use in Stroke (VENUS): A randomized, double-blind, placebo-controlled trial. Stroke 2001; 32: 461-465.
  8. Hsu CY, Norris JW, Hogan EL, et al. Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial. Stroke 1988; 19: 716-722.
  9. Muir KW, Holzapfel L, Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 2000; 10: 431-436.
  10. Haley EC Jr. High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. Stroke 1998; 29: 1256-1257.
  11. The Syngen in Acute Stroke Study Investigators. Ganglioside GM1 in acute ischemic stroke. The SASS Trial. Stroke 1994; 25: 1141-1148.
  12. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30: 2592-2597.
  13. Clark WM, Raps EC, Tong DC, et al. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000; 31: 1234-1239.
  14. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999; 30: 21-28.
  15. The CORAMI Study Group. Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. Cohort of rescue angioplasty in myocardial infarction. Am J Cardiol 1994; 74: 172-174.
  16. Belenkie I, Traboulsi M, Hall CA, et al. Rescue angioplasty during myocardial infarction has a beneficial effect on mortality: a tenable hypothesis. Can J Cardiol 1992; 8: 357-362.
  17. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Am J Cardiol 999; 84: 779-784.
  18. Cantor WJ, Kaplan AL, Velianou JL, et al. Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol 2001; 87: 439-442.
  19. Ferguson JJ, Taqi K. IIb-IIIa receptor blockade in acute myocardial infarction. Am Heart J 1999; 138: S164-170.
  20. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb-IIIa receptor blockade in coronary artery disease. Circulation 2000; 35: 1103-1115.
  21. DeLemos JA, Antman EM, Gibson M, et al. Abciximab improves both epicardial flow and endocardial reperfusion in ST elevation MI: a TIMI 14 analysis [abstr]. Circulation 1999; 100(suppl I): I-649.
  22. Herrmann HC, Moliterno DJ, Bode C, et al. Combination abciximab and reduced-dose reteplase facilitates early PCI in myocardial infarction: Results from the SPEED trial [abstr]. Circulation 1999; 100(suppl I): I-188.
  23. Lanzieri CF, Tarr RW, Landis D, Selman WR, Lewin JS, Adler LP, Silvers JB. Cost effectiveness of emergency intra-arterial intracerebral thrombolysis: A pilot study. AJNR 1995; 16: 1987-1993.
  24. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989; 20: 864-870.
  25. Overgaard K. Thrombolytic therapy in experimental embolic stroke. Cerebrovasc Brain Metab Review 1994; 6: 257-286.
  26. Heiss WD, Graf R, Weinhard J, et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow and Metab 1994; 14; 892-902.
  27. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurol 1992; 42: 976-982.
  28. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992; 23: 646-652.
  29. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
  30. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European cooperative acute stroke study (ECASS). JAMA 1995; 274: 1017-1025.
  31. Hacke W. Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245-1251.
  32. Clark W, Wissman S, Albers G, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study; A randomized controlled trial. JAMA 1999: 282: 2019-2026.
  33. Katzan IL, Sila CA, Furlan AJ, et al. Community use of intravenous tissue plasminogen activator for acute stroke: Results of the Brain Matters Stroke Management Survey. Stroke 2001; 32: 861-865.
  34. Handschu R, Garling A, Heuschmann PU, et al. Acute stroke management in the local general hospital. Stroke 2001 32: 866-870.
  35. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR 1996; 17: 79-85.
  36. Zeumer H, Freitag H-J, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993; 35: 159-162.
  37. Brandt T, von Kummer R, Müller-Küppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996; 27: 875-881.
  38. Hacke W, Zeumer H, Ferbert A, Brückmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-1222.
  39. Higashida RT, Halbach VV, Barnwell SL, Dowd CF, Hieshima GB. Thrombolytic therapy in acute stroke. J Endovasc Surg 1994; 1: 4-15.
  40. Theron J, Coskun O, Huet H, Oliveira G, Toulas P, Payelle G. Local intraarterial thrombolysis in the carotid territory. Interventional Neuroradiology 1996; 2: 111-126.
  41. Theron J., Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. AJNR 1989; 10: 753-765.
  42. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4-11.
  43. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4-11.
  44. Lewandowski C, Frankel M, Tomsick T, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30: 2598-2605.
  45. Van Swieten JC, Koudsteil PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1987; 19: 604-607.
  46. Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000; May 13; 355: 1670-1674. Erratum in: Lancet 2000 Jun 17; 355 (9221): 2170.
  47. Pexman JH, Barber PA, Hill MD, Sevick RJ, Demchuk AM, Hudon ME, Hu WY, Buchan AM. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol. 2001 Sep;22(8):1534-42.

 
 
Copyright © 2007 Stroke Registry
webmaster